tebipenem

Small moleculeexperimental

Tebipenem is a broad-spectrum orally-administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics. Tebipenem is formulated as the ester tebipenem pivoxil due to the better absorption and improved bioavailability of this form. It has performed well in clinical trials for ear infection and looks likely to be further developed in future. It is only marketed in Japan. Tebipenem is the first carbapenem whose prodrug form, the pivalyl ester, is orally available. — Wikipedia

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](O)[C@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(SC3CN(C4=NCCS4)C3)[C@H](C)[C@H]12
Mol. weight
497.64 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • orapenem
  • tebipenem pivoxil
  • tebipenem pivoxil
  • tebipenem pivoxil
  • tebipenem pivoxil
  • tebipenem pivoxil

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06727136Phase 1Nov 20, 2024GlaxoSmithKline, Spero Therapeutics
NCT06059846Phase 3Nov 30, 2023GlaxoSmithKline, Spero Therapeutics
NCT05856747Phase 1May 4, 2023Spero Therapeutics
NCT05121974Phase 2Dec 31, 2021GlaxoSmithKline, International Center for Diarrheal Disease Research, University of Washington
NCT04919954Phase 1Aug 31, 2021Spero Therapeutics, University of Connecticut
NCT04710407Phase 1Dec 7, 2020Clinartis, Pulmonary Associates, Phoenix, AZ, Spero Therapeutics
NCT04625855Phase 1Sep 30, 2020Covance, Spero Therapeutics
NCT04421885Phase 1Jun 1, 2020Spero Therapeutics
NCT04368585Phase 1May 31, 2020Spero Therapeutics
NCT04376554Phase 1Feb 10, 2020IQVIA, Karolinska Institute, Spero Therapeutics
NCT04238195Phase 1Jan 19, 2020Celerion, Spero Therapeutics
NCT04178577Phase 1Dec 31, 2019Spero Therapeutics
NCT03788967Phase 3Jun 3, 2019Spero Therapeutics
NCT03395249Phase 1Oct 20, 2017CPR Pharma Services Pty Ltd, Australia, Scientia Clinical Research Limited Sydney, Spero Therapeutics
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Spero TherapeuticsFor profit131222017
GlaxoSmithKlineFor profit3032021
CelerionFor profit1012020
ClinartisFor profit1012020
CovanceFor profit1012020
CPR Pharma Services Pty Ltd, AustraliaFor profit1012017
International Center for Diarrheal Disease ResearchAcademic/Hospital1112021
IQVIAFor profit1012020
Karolinska InstituteAcademic/Hospital1012020
Pulmonary Associates, Phoenix, AZAcademic/Hospital1012020
Scientia Clinical Research Limited SydneyFor profit1012017
University of ConnecticutAcademic/Hospital1112021
University of WashingtonAcademic/Hospital1012021
13 organizations
Page 1 / 1